Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
May 10, 2017 7:30 AM EDTPositive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
Continued Progress in the Commercialization of alfataliglicerase in Brazil
CARMIEL, Israel, May 10, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based... More
